JUN 0 7 2004 E

it 1645 Bl93

PTO/SB/21 (02-04) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE der the Paperwork Reduction Act of 1995, no persons are required to respond to collection of information unless it displays a valid OMB control number. Application Number 09/677.752 TRANSMITTAL Filing Date 10/03/2000 **FORM** First Named Inventor W. James Jackson, et al. Art Unit 1645 (to be used for all correspondence after initial filing) Examiner Name Ford, Vanessa L. Attorney Docket Number 087-999 Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance communication Fee Transmittal Form Drawing(s) to Technology Center (TC) Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to TC Amendment/Reply (Appeal Notice, Brief, Reply Brief) Petition to Convert to a After Final Proprietary Information **Provisional Application** Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Enclosure(s) (please Terminal Disclaimer Extension of Time Request Identify below): Cited References Request for Refund **Express Abandonment Request** Return Postcard CD, Number of CD(s) Information Disclosure Statement Remarks Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT John M. Naber (Reg. No. 46,487) Individual name Signature Date June 3, 2004 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below. Typed or printed name Trudy Meade Date Signature

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

plication of:

W. James Jackson,

Confirmation No.:

5261

et al

Serial No.

09/677,752

Art Unit:

1645

Filed:

10/03/2000

Examiner:

Ford, Vanessa L.

For:

Chlamydia Protein, Gene

Atty Docket No.:

087-999

Sequence and Uses Thereof

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

## FIFTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application. Attorneys for Applicant hereby direct the Examiner's attention to the References CE - CQ listed on the attached revised PTO-1449 form.

Applicant respectfully requests that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

As this statement is being submitted under 37 C.F.R. § 1.97(b)(4), before the mailing of a first Office Action after the filling of a request for continued examination under § 1.114.

Respectfully submitted.

Dated: 3 June 2004

Bv:

nn M. Naber (Reg. No. 46,487)

Foster, Swift, Collins & Smith, P.C. 313 South Washington Square

Lansing, MI 48933

(517) 371-8100 telephone/(517)371-8200 fax

Substitute Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No.	087-999	Application No.	09/677,752	
Information Disclosure Statement by Applicant		Applicant W. James Jackson				
(Use several sheets	if necessary)	Filing Date	10-03-2000	Group Art Unit	1645	

& TRADEN							1040
U.S. Patent Documents							
Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
	CE	US 5,965,141	10-12-1999	Briles et al			
	CF	US 5,976,544	11-02-1999	Charles et al			

		Other Documents (include Author, Title, Date, and Place of Publication)
Examiner Initial	Desig. ID	Document
	CG	Deslauriers, et al, Identification of Murine Protective Epitopes on the <i>Porphyromonas gingivalis</i> Fimbrillin Molecule, Infection and Immunity, 64:434 (1996)
	СН	Ji, et al, Intranasal Immunization with C5a Peptidase Prevents Nasopharyngeal Colonization of Mice by the Group A Streptococcus, Infection and Immunity, 65:2080 (1997)
	СІ	Nilsson, et al, Vaccination with a Recombinant Fragment of Collagen Adhesin Provides Protection against Staphylococcus Aureus-mediated Septic Death, J. Clin. Invest., 101:2640 (1998)
	CJ	Sexton, et al, Vaccination of Sheep Against Fasciola Hepatica with Glutathione S-transferase. Identification and Mapping of Antibody Epitopes on a Three-Dimensional Model of the Antigen, J. Immunology, 152:1861 (1994)
	ск	Tanzer, et al, Characterization of Outer Membrane Proteins in <i>Chlamydia trachomatis</i> LGV Serovar L2, J. Bacteriology, 183:2686 (2001)
	CL	Exner, et al, Protection Elicited by Native Outer Membrane Protein Oms66 (p66) against Host-Adapted Borrelia burgdorferi: Conformational Nature of Bactericidal Epitopes, Infection and Immunity, 68:2647 (2000)
	СМ	Grimwood, et al, Expression of <i>Chlamydia pneumoniae</i> Polymorphic Membrane Protein Family Genes, Infection and Immunity, 69:2383 (2001)
	CN	Christiansen, et al, Potential Relevance of <i>Chlamydia pneumoniae</i> Surface Proteins to an Effective Vaccine, J. Infectious Diseases, 181(Suppl 3):S528 (2000)
	со	Stothard, et al, Polymorphic Membrane Protein H Has Evolved in Parallel with the Three Disease-Causing Groups of <i>Chlamydia trachomatis</i> , Infection and Immunity, 71:1200 (2003)
	СР	Mygind, et al, Membrane Proteins PmpG and PmpH are Major Constituents of <i>Chlamydia trachomatis</i> L2 Outer Membrane Complex, FEMS Microbiol Lett., 186(2):163 (2000)
	CQ	Hou, et al, Conformational Epitopes Recognized by Protective Anti-Neisserial Surface Protein A Antibodies, Infection and Immunity, 71(12):6844 (2003)

Examiner Signature	Considered
EXAMINER: Initials citation considered. Draw line through citation	on if not in conformance and not considered. Include conv. of this

EARMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.